existing formulations of 611

Phase 1Small molecule

SSunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

existing formulations of 611 is one of 19 small molecule programs targeting Adult Subject. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Adult SubjectNot yet recruiting

Adult SubjectPhase 1

Not yet recruiting

Competition

Competitive Landscape

25 competitors in Adult Subject

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 1

1 2

Abraxane

Bristol-Myers Squibb

Phase 1

1 3

Gemzar

Johnson & Johnson

Phase 1

1 4

Bayer Aspirin

Bayer

Phase 1

1 5

Alimta

SShawn Eagle

Phase 1

1 6

Erbitux

IImclone

Phase 1

1 7

FOLFOX

AstraZeneca

Phase 1

1 8

NALIRIFOX

TTheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

Phase 1

1 9

SNUG01

SSineuGene Therapeutics Co., Ltd.

Phase 2

1 10

Miricorilant

CCorcept Therapeutics

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Adult Subject1 trial

A Study of Two Different Formulations of 611 in Healthy Adult Subjects in China

Not yet recruiting·SSunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.·Phase 1·NCT07042113·180 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for existing formulations of 611. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — existing formulations of 611 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for existing formulations of 611. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: SSunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

existing formulations of 611

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Adult Subject1 trial

References

Drug Info

Quick Facts

Related News